Lowest Price Guaranteed From USD 4,799
Published
October 2022
Pages
640
View Count
22908
Example Insights
Please refer below for insights
Report Description
Global CAR T cell therapy market size is poised to reach USD 25 billion by 2035, growing at a CAGR of 20% from 2022 to 2035. Cancer is one of the leading cause of deaths, globally. In fact, as per the World Health Organization (WHO), 10 million cancer related deaths were reported in 2020. Further, it is estimated that, by the end of 2040, 27.5 million new cases will be added to the global cancer burden, exerting tremendous physical, emotional and financial strain on affected individuals, their families, communities as well as the national health systems. Even though a number of treatment options are available to control disease progression and keep malignant cells from spreading throughout the body, lasting remission is still difficult to achieve. Amidst the active initiatives undertaken to develop more targeted anti-cancer therapies, CAR T cell therapies have emerged as a promising option, given their ability to eradicate tumor cells from the body with minimal treatment-related side effects. Further, CAR-T immunotherapies, a relatively recent addition to the gamut of anticancer interventions, have demonstrated significant promise. Overall, this highly specific and promising form of cell therapy, which harnesses the versatile effector machinery of the human immune system, has revolutionized cancer treatment, globally. Given the consistent increase in number of cell therapies being developed and launched, this upcoming CAR T-cell therapy market is on its way to becoming one of the highest valued markets within the biopharmaceutical industry.
![]() |
![]() |
![]() |
![]() |
![]() |
The CAR T Cell Therapy Market (4th Edition) by Key Drugs (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Ciltacabtagene Autoleucel, Lisocabtagene Maraleucel, Others), Target Indications (Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Acute Myeloid Leukemia, Ovarian Cancer, Generalized Myasthenia Gravis And Renal Cell Carcinoma), Target Antigens (CD19, BCMA, CD19 / CD22, EGFR, NY-ESO-1 and Others), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Global Forecast 2022-2035 report features an extensive study of the current market size and the future potential of CAR-T therapies. The report highlights the efforts of both industry players and academic organizations in this rapidly evolving segment of the biopharmaceutical industry. Amongst other elements, the market report answers several key questions related to the market.
At present, of the seven approved CAR T cell therapies, six have been approved for several hematological malignancies in the US; these are Tisagenlecleucel-T (KYMRIAH®), Axicabtagene ciloleucel (YESCARTA®), Brexucabtagene Autoleucel (TECARTUS™), Lisocabtagene maraleucel (Breyanzi®), Idecabtagene Vicleucel (Abecma™) and Ciltacabtagene Autoleucel (CARVYKTI™). With 679 therapy programs in the clinical phases of development, CAR-T cell therapies have already established a strong foothold in the overall pharmaceutical industry. In addition, there are 289 CAR-T cell therapy programs in the preclinical stages of development that are likely to emerge as potential therapy candidates in the long term. The currently approved CAR-T therapies target the CD19 receptor and BCMA. However, CAR-T companies are developing therapies against several other novel targets that have been analyzed in this report. The expected launch of several promising leads over the forecast period, will drive the market growth.
170+ CAR T cell therapy companies are engaged in the development of over 970 early and late-stage CAR-T therapies, worldwide. More than 260 collaborations have been inked between several industry / academic stakeholders in order to advance the development of various pipeline candidates. To fund CAR-T cell therapy development, capital investments worth more than USD 24 billion have been made by various private and public sector investors, in the last few years. Additionally, over 6,500 patents related to CAR-T cell therapy have been recently filed / granted, demonstrating the continued innovation in this market. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the CAR T-cell therapy market size is likely to witness significant growth during the forecast period.
According to the cancer data published by World Cancer Research Fund International, there were 474,519 new cases of leukemia, 176,404 new cases of multiple myeloma and 627,439 new cases of lymphoma worldwide in 2020. Many of the approved and clinical stage CAR T cell therapies target these hematological indications. Rising incidence and prevalence of cancer, as well as an increase in the relapse / remission rates will drive the adoption of CAR T cell therapies, driving the market growth. The developers of Idecabtagene Vicleucel (BMS) and Ciltacabtagene Autoleucel (Janssen and Legend Biotech) have published positive results from phase III trials for the treatment of multiple myeloma as earlier line of treatment compared to the currently approved status as fifth line therapies. Such developments will expand the potential market size for CAR-T therapies.
On the basis of region, North America held 54% market share in terms of revenues generated through sales of approved CAR T cell therapies. This is likely to change during the forecast period, as Europe is projected to hold more than 37% share of the global market size. Although the process of approval of CAR-T therapies is accelerated through various grants, the high prices of treatment options continue to be one of the key challenges associated with CAR T cell therapy adoption. In the UK, Yescarta and Kymriah have been to date provided through National Health Services’s (NHS) Cancer Drugs Fund. However, this situation is likely to change as National Institute for Health and Care Excellence (NICE) is working on gathering evidence on cost-effectiveness of Yescarta. If approved, Axicabtagene Ciloleucel will become the first CAR T cell therapy to be provided to the patients through NHS. The European market will continue to grow at a healthy CAGR during the forecast period of this market report.
Manufacturing biologics and cell therapies is considerably complex, as compared to small molecule drugs. The high manufacturing cost also contributes to high price of the therapy, essentially leading to limited adoption in case of unavailability of reimbursement. In 2021, BMS faced manufacturing bottleneck for its CAR-T idecabtagene vicleucel (ABECMA®), driven by shortage of viral vectors in addition to other reasons. In 2022, Janseen and Legend Biotech rolled out their CAR-T ciltacabtagene autoleucel (CARVYKTI ®) in a phased manner in the US instead of a nationwide launch owing to manufacturing limitations.
These challenges may be temporary as the market matures and is supported by the cell therapy contract manufacturers.
![]() |
![]() |
![]() |
![]() |
![]() |
Several recent developments have taken place in the field of CAR T cell therapy. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
Report Attribute | Details | |
Forecast Period |
2022 – 2035 |
|
Market Size 2035 | $25 billion | |
CAGR | 20% | |
Base Year | 2021 | |
Target Indications |
Non-Hodgkin's Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Hodgkin's Lymphoma, Acute Myeloid Leukemia, Ovarian Cancer, Generalized Myasthenia Gravis, Renal Cell Carcinoma |
|
Target Antigens |
CD19, BCMA, CD19/CD22, Others | |
Key Players |
Bristol Myers Squibb, Gilead Sciences, Novartis, Autolus, Janssen, JW Therapeutics, Beijing Immunochina Medical Science & Technology, Bioray Laboratories |
|
Key Geographies |
North America, Europe, Asia-Pacific, Middle East and North Africa, Latin America, Rest of the World |
The market research report features an extensive study of the current market size and the future potential of CAR-T therapies. The report highlights the efforts of both industry players and academic organizations in this rapidly evolving segment of the biopharmaceutical industry. Amongst other elements, the report features the following:
One of the key objectives of the report was to estimate the CAR T therapy market size and identify potential growth opportunities for CAR-T cell therapies over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the period 2022-2035. The report also includes likely sales forecasts of CAR T cell therapies that are already marketed or in the late stages of development. Additionally, it features market size projections for the overall CAR T-cell therapy market, wherein opportunity has been segmented across [A] key drugs (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Ciltacabtagene Autoleucel, Lisocabtagene Maraleucel, Others), [B] target indications (non-hodgkin lymphoma, multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, generalized myasthenia gravis and renal cell carcinoma), [C] target antigens (CD19, BCMA, CD19 / CD22 and others), Key Players and [D] key geographies (North America (US and Canada), Europe (UK, Germany, France, Italy, Spain and rest of EU), Asia Pacific (China, Japan, Australia), Latin America, Latin America, Middle East and North Africa and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.
![]() |
![]() |
![]() |
The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.
Contents
1. PREFACE
1.1. Chapter Overview
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapies
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapy
3.5.1. By Mechanism of Action
3.5.1.1. Active Immunotherapy
3.5.1.2. Passive Immunotherapy
3.5.2. By Type of Target
3.5.3. By Approach
3.5.3.1. Activation and Suppression Immunotherapy
3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Oncolytic Virus Therapy
3.5.4.5. Therapeutic Cancer Vaccines
3.5.4.6. Cell-based Therapies
3.6. T-Cell Immunotherapies
3.6.1. Historical Evolution
3.6.2. Key Considerations for Developing T-Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing of Engineered T-Cells
3.6.5. T-Cell Transduction and Transfection Methods
3.6.5.1. Retroviral Vectors
3.6.5.2. Lentiviral Vectors
3.6.5.3. Non-viral Transfection Methods
3.7. Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
3.7.1. Development History
3.7.2. Anatomical Layout of CAR
3.7.2.1. Ectodomain
3.7.2.2. Transmembrane (TM) Domain
3.7.2.3. Endodomain
3.7.3. Development of CAR-T Cells
3.7.4. Universal CAR-T Cells
3.7.5. Route of Administration
3.7.6. Case Study on CD19 CAR-T Cell Therapies
3.7.6.1. Other Important Biological Targets for CAR Development
3.7.7. Challenges Associated with CAR-T Cell Therapies
3.7.7.1. Competitive Risks
3.7.7.2. Clinical Risks
3.7.7.3. Regulatory Risks
3.7.7.4. Commercial Risks
3.8. Concluding Remarks
4. CAR T CELL THERAPY: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. CAR T Cell Therapy: Overall Market Landscape
4.2.1. Analysis by Type of Developer
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Phase of Development and Therapeutic Area
4.2.5. Analysis by Key Target Indication
4.2.6. Analysis by Key Target Antigen
4.2.7. Analysis by Source of T-Cells
4.2.8. Analysis by Phase of Development and Source of T-Cells
4.2.9. Analysis by Route of Administration
4.2.10. Analysis by Dosing Frequency
4.2.11. Analysis by Target Patient Segment
4.2.12. Analysis by Type of Therapy
4.2.13. Most Active Industry Players: Analysis by Number of CAR T-Cell Therapies
4.2.14. Most Active Non-Industry Players: Analysis by Number of CAR T-Cell Therapies
4.3. CAR T Cell Therapy: Overall Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
5. KEY INSIGHTS
5.1. Chapter Overview
5.2. CAR T-Cell Therapies: Competitive Analysis of Popular Target Antigens
5.2.1. Popular Targets Related to Hematological Malignancies
5.2.2. Popular Targets Related to Solid Tumors
5.3. T-Cell Immunotherapies: CAR Construct Analysis
5.3.1. Analysis by Generation of CAR
5.3.2. Analysis by Type of scFv Antibody
5.3.3. Analysis by Type of Virus Used
5.3.4. Analysis by Type of Gene Transfer Method Used
5.3.5. Analysis by Type of Co-Stimulatory Domain
6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. CAR T-Cell Therapies: Clinical Trial Analysis
6.3.1. Analysis of Trials by Trial Registration Year
6.3.2. Analysis of Enrolled Patient Population by Trial Registration Year
6.3.3. Analysis by Trial Status
6.3.4. Analysis by Trial Registration Year and Trial Status
6.3.5. Analysis by Trial Phase
6.3.6. Analysis of Enrolled Patient Population by Trial Phase
6.3.7. Analysis by Target Patient Segment
6.3.8. Analysis by Type of Sponsor / Collaborator
6.3.9. Analysis by Study Design
6.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
6.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
6.3.12. Analysis by Key Focus Areas
6.3.13. Analysis of Trials by Geography
6.3.14. Analysis of Enrolled Patient Population by Geography
7. KEY OPINION LEADERS
7.1. Chapter Overview
7.2. Assumptions and Key Parameters
7.3. Methodology
7.4. CAR-T Cell Therapies: Key Opinion Leaders
7.4.1. Analysis by Type of Organization
7.4.2. Analysis by Affiliated Organization
7.4.3. Analysis by Qualification
7.4.4. Analysis by Geographical Location of KOLs
7.4.5. KOL Activeness versus KOL Strength
7.4.6. Most Prominent KOLs: Analysis by RA score
7.4.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score
8. CAR-T CELL THERAPY PROFILES
8.1. Chapter Overview
8.2. Kymriah / Tisagenlecleucel / CTL019 (Novartis)
8.2.1. Therapy Overview
8.2.2. Clinical Trial Information
8.2.3. Clinical Trial Endpoints
8.2.4. Clinical Trial Results
8.2.5. Estimated Sales Revenues
8.3. Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences)
8.3.1. Therapy Overview
8.3.2. Clinical Trial Information
8.3.3. Clinical Trial Endpoints
8.3.4. Clinical Trial Results
8.3.5. Estimated Sales Revenues
8.4. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
8.4.1. Therapy Overview
8.4.2. Clinical Trial Information
8.4.3. Clinical Trial Endpoints
8.4.4. Clinical Trial Results
8.4.5. Estimated Sales Revenues
8.5. Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb)
8.5.1. Therapy Overview
8.5.2. Clinical Trial Information
8.5.3. Clinical Trial Endpoints
8.5.4. Clinical Trial Results
8.5.5. Estimated Sales Revenues
8.6. Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb)
8.6.1. Therapy Overview
8.6.2. Clinical Trial Information
8.6.3. Clinical Trial Endpoints
8.6.4. Clinical Trial Results
8.6.5. Estimated Sales Revenues
8.7. Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen)
8.7.1. Therapy Overview
8.7.2. Clinical Trial Information
8.7.3. Clinical Trial Endpoints
8.7.4. Clinical Trial Results
8.7.5. Estimated Sales Revenues
8.8. Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics)
8.8.1. Therapy Overview
8.8.2. Clinical Trial Information
8.8.3. Clinical Trial Endpoints
8.8.4. Clinical Trial Results
8.8.5. Estimated Sales Revenues
8.9. TBI-1501 / CD19 CAR-T Cell Therapy (Takara Bio)
8.9.1. Therapy Overview
8.9.2. Clinical Trial Information
8.9.3. Clinical Trial Endpoints
8.10. AUTO1 / Obecabtagene Autoleucel / obe-cel (Autolus)
8.10.1. Therapy Overview
8.10.2. Clinical Trial Information
8.10.3. Clinical Trial Endpoints
8.10.4. Clinical Trial Results
8.10.5. Estimated Sales Revenues
8.11. AUTO3 / CD19/22 CAR-T (Autolus)
8.11.1. Therapy Overview
8.11.2. Clinical Trial Information
8.11.3. Clinical Trial Endpoints
8.11.4. Clinical Trial Results
8.11.5. Estimated Sales Revenues
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. CAR-T Cell Therapies: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year of Partnership and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Most Popular Products: Analysis by Number of Partnerships
9.3.6. Most Active Industry Players: Analysis by Number of Partnerships
9.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships
9.3.8. Analysis by Geography
9.3.8.1. Intercontinental and Intracontinental Deals
9.3.8.2. International and Local Deals
10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. CAR-T Cell Therapies: Funding and Investment Analysis
10.3.1. Analysis of Instances by Year
10.3.2. Analysis of Amount Invested by Year
10.3.3. Analysis by Type of Funding
10.3.4. Analysis by Type of Investor
10.3.5. Most Active Players: Analysis by Number of Instances
10.3.6. Most Active Investors: Analysis by Amount Invested
10.3.7. Analysis of Amount Invested by Geography
10.3.8. Most Active Investors: Analysis by Number of Funding Instances
11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. CAR-T Cell Therapies: Patent Analysis
11.3.1. Analysis by Patent Publication Year
11.3.2. Analysis by Patent Application Year
11.3.3. Analysis by Geography
11.3.4. Analysis by Type of Player
11.3.5. Analysis by CPC Symbols
11.3.6. Analysis by Key Focus Area
11.3.7. Leading Players: Analysis by Number of Patents
11.3.8. CAR T-Cell Therapies: Patent Benchmarking
11.3.9. Analysis By Patent Characteristics
11.3.10. CAR T-Cell Therapies: Patent Valuation
12. CASE STUDY: CELL THERAPY MANUFACTURING
12.1. Chapter Overview
12.2. Overview of Cell Therapy Manufacturing
12.3. Cell Therapy Manufacturing Models
12.3.1. Centralized Manufacturing Model
12.3.2. Decentralized Manufacturing Model
12.4. Scalability of Cell Therapy Manufacturing Processes
12.4.1. Scale-Up
12.4.2. Scale-Out
12.5. Types of Cell Therapy Manufacturers
12.6. Key Challenges Related to Manufacturing of Cell Therapies
12.7. Key Considerations for Cell Therapy Manufacturing
12.7.1. Characterization
12.7.2. Cost of Goods
12.8. Automation of Cell Therapy Manufacturing Process
12.9. Cell Therapy Manufacturing Supply Chain
12.10. Comparison of Players Having In-House Capabilities and Contract Manufacturers
12.11. Regulatory Landscape
12.12. Future Perspectives
13. COST PRICE ANALYSIS
13.1. Chapter Overview
13.2. Factors Contributing to the High Price of Cell / Gene Therapies
13.3. Pricing Models for T-Cell Immunotherapies
13.3.1. Based on Associated Costs
13.3.2. Based on Availability of Competing Products
13.3.3. Based on Patient Segment
13.3.4. Based on Opinions of Industry Experts
13.4. Reimbursement related Considerations for T-cell Immunotherapies
13.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T therapies
14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Scope and Limitations
14.3. Key Assumptions and Forecast Methodology
14.4. Global CAR T Cell Therapy Market, 2022-2035
14.4.1. CAR T Cell Therapy Market: Analysis by Target Indication
14.4.2. CAR T Cell Therapy Market: Analysis by Target Antigen
14.4.3. CAR T Cell Therapy Market: Analysis by Key Players
14.4.4. CAR T Cell Therapy Market: Analysis by Geography
14.4.5. Product Wise Sales Forecast
14.4.5.1. Kymriah / Tisagenlecleucel / CTL019 (Novartis)
14.4.5.1.1. Sales Forecast (USD Million)
14.4.5.1.2. Net Present Value
14.4.5.1.3. Value Creation Analysis
14.4.5.2. Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences)
14.4.5.2.1. Sales Forecast (USD Million)
14.4.5.2.2. Net Present Value (USD Million)
14.4.5.2.3. Value Creation Analysis
14.4.5.3. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
14.4.5.3.1. Sales Forecast (USD Million)
14.4.5.3.2. Net Present Value (USD Million)
14.4.5.3.3. Value Creation Analysis
14.4.5.4. Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb)
14.4.5.4.1. Sales Forecast (USD Million)
14.4.5.4.2. Net Present Value (USD Million)
14.4.5.4.3. Value Creation Analysis
14.4.5.5. Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen)
14.4.5.5.1. Sales Forecast (USD Million)
14.4.5.5.2. Net Present Value (USD Million)
14.4.5.5.3. Value Creation Analysis
14.4.5.6. Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb)
14.4.5.6.1. Sales Forecast (USD Million)
14.4.5.6.2. Net Present Value (USD Million)
14.4.5.6.3. Value Creation Analysis
14.4.5.7. Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics)
14.4.5.7.1. Sales Forecast (USD Million)
14.4.5.7.2. Net Present Value (USD Million)
14.4.5.7.3. Value Creation Analysis
14.4.5.8. BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology)
14.4.5.8.1. Sales Forecast (USD Million)
14.4.5.8.2. Net Present Value (USD Million)
14.4.5.8.3. Value Creation Analysis
14.4.5.9. CD19 CAR-T (Wuhan Si'an Medical Technology)
14.4.5.9.1. Sales Forecast (USD Million)
14.4.5.9.2. Net Present Value (USD Million)
14.4.5.9.3. Value Creation Analysis
14.4.5.10. Descartes-11 (Cartesian Therapeutics)
14.4.5.10.1. Sales Forecast (USD Million)
14.4.5.10.2. Net Present Value (USD Million)
14.4.5.10.3. Value Creation Analysis
14.4.5.11. Descartes-08 (Cartesian Therapeutics)
14.4.5.11.1. Sales Forecast (USD Million)
14.4.5.11.2. Net Present Value (USD Million)
14.4.5.11.3. Value Creation Analysis
14.4.5.12. Zamtocabtagene Autoleucel MB-CART19.1 (Miltenyi Biomedicine)
14.4.5.12.1. Sales Forecast (USD Million)
14.4.5.12.2. Net Present Value (USD Million)
14.4.5.12.3. Value Creation Analysis
14.4.5.13. CNCT19 / HY001 (Juventas Cell Therapy)
14.4.5.13.1. Sales Forecast (USD Million)
14.4.5.13.2. Net Present Value (USD Million)
14.4.5.13.3. Value Creation Analysis
14.4.5.14. CD30.CAR-T / TT11 (Tessa Therapeutics)
14.4.5.14.1. Sales Forecast (USD Million)
14.4.5.14.2. Net Present Value (USD Million)
14.4.5.14.3. Value Creation Analysis
14.4.5.15. TAK-007 (Takeda)
14.4.5.15.1. Sales Forecast (USD Million)
14.4.5.15.2. Net Present Value (USD Million)
14.4.5.15.3. Value Creation Analysis
14.4.5.16. AUTO1 (Autolus)
14.4.5.16.1. Sales Forecast (USD Million)
14.4.5.16.2. Net Present Value (USD Million)
14.4.5.16.3. Value Creation Analysis
14.4.5.17. AUTO3 (Autolus)
14.4.5.17.1. Sales Forecast (USD Million)
14.4.5.17.2. Net Present Value (USD Million)
14.4.5.17.3. Value Creation Analysis
14.4.5.18. CD19 CAR-T (Bioray Laboratories)
14.4.5.18.1. Sales Forecast (USD Million)
14.4.5.18.2. Net Present Value (USD Million)
14.4.5.18.3. Value Creation Analysis
14.4.5.19. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
14.4.5.19.1. Sales Forecast (USD Million)
14.4.5.19.2. Net Present Value (USD Million)
14.4.5.19.3. Value Creation Analysis
14.4.5.20. IM19 CAR-T (Beijing Immunochina Medical Science & Technology)
14.4.5.20.1. Sales Forecast (USD Million)
14.4.5.20.2. Net Present Value (USD Million)
14.4.5.20.3. Value Creation Analysis
14.4.5.21. CCT301 CAR-T Cell Therapy (Shanghai Sinobioway Sunterra Biotech)
14.4.5.21.1. Sales Forecast (USD Million)
14.4.5.21.2. Net Present Value (USD Million)
14.4.5.21.3. Value Creation Analysis
14.4.5.22. BinD19 (Shenzhen BinDeBio)
14.4.5.22.1. Sales Forecast (USD Million)
14.4.5.22.2. Net Present Value (USD Million)
14.4.5.22.3. Value Creation Analysis
14.4.5.23. CARCIK-CD19 (CoImmune)
14.4.5.23.1. Sales Forecast (USD Million)
14.4.5.23.2. Net Present Value (USD Million)
14.4.5.23.3. Value Creation Analysis
14.4.5.24. PBCAR269A (Precision BioSciences / Servier)
14.4.5.24.1. Sales Forecast (USD Million)
14.4.5.24.2. Net Present Value (USD Million)
14.4.5.24.3. Value Creation Analysis
14.4.5.25. CD123 CAR-T cells Therapy (Chongqing Precision Biotechnology)
14.4.5.25.1. Sales Forecast (USD Million)
14.4.5.25.2. Net Present Value (USD Million)
14.4.5.25.3. Value Creation Analysis
14.4.5.26. BCMA CAR-T (Chongqing Precision Biotech)
14.4.5.26.1. Sales Forecast (USD Million)
14.4.5.26.2. Net Present Value (USD Million)
14.4.5.26.3. Value Creation Analysis
14.4.5.27. CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
14.4.5.27.1. Sales Forecast (USD Million)
14.4.5.27.2. Net Present Value (USD Million)
14.4.5.27.3. Value Creation Analysis
14.4.5.28. GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology)
14.4.5.28.1. Sales Forecast (USD Million)
14.4.5.28.2. Net Present Value (USD Million)
14.4.5.28.3. Value Creation Analysis
14.4.5.29. iC9-CAR19 T cells (Bellicum Pharmaceuticals)
14.4.5.29.1. Sales Forecast (USD Million)
14.4.5.29.2. Net Present Value (USD Million)
14.4.5.29.3. Value Creation Analysis
14.4.5.30. ALLO-501A / ALLO-501 (Allogene Therapeutics)
14.4.5.30.1. Sales Forecast (USD Million)
14.4.5.30.2. Net Present Value (USD Million)
14.4.5.30.3. Value Creation Analysis
14.4.5.31. CD19/CD20-CAR-T (Yake Biotechnology)
14.4.5.31.1. Sales Forecast (USD Million)
14.4.5.31.2. Net Present Value (USD Million)
14.4.5.31.3. Value Creation Analysis
14.4.5.32. CD7 CAR-T (PersonGen BioTherapeutics)
14.4.5.32.1. Sales Forecast (USD Million)
14.4.5.32.2. Net Present Value (USD Million)
14.4.5.32.3. Value Creation Analysis
14.4.5.33. Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics)
14.4.5.33.1. Sales Forecast (USD Million)
14.4.5.33.2. Net Present Value (USD Million)
14.4.5.33.3. Value Creation Analysis
14.4.5.34. CT053 (CARsgen Therapeutics)
14.4.5.34.1. Sales Forecast (USD Million)
14.4.5.34.2. Net Present Value (USD Million)
14.4.5.34.3. Value Creation Analysis
14.4.5.35. Anti-ALPP CAR-T Cells (TCRCure Biopharma)
14.4.5.35.1. Sales Forecast (USD Million)
14.4.5.35.2. Net Present Value (USD Million)
14.4.5.35.3. Value Creation Analysis
14.4.5.36. BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology)
14.4.5.36.1. Sales Forecast (USD Million)
14.4.5.36.2. Net Present Value (USD Million)
14.4.5.36.3. Value Creation Analysis
14.4.5.37. ALLO-605 (Allogene Therapeutics)
14.4.5.37.1. Sales Forecast (USD Million)
14.4.5.37.2. Net Present Value (USD Million)
14.4.5.37.3. Value Creation Analysis
14.4.5.38. WU CART 007 (Wugen)
14.4.5.38.1. Sales Forecast (USD Million)
14.4.5.38.2. Net Present Value (USD Million)
14.4.5.38.3. Value Creation Analysis
14.4.5.39. CT103A (Nanjing IASO Biotherapeutics)
14.4.5.39.1. Sales Forecast (USD Million)
14.4.5.39.2. Net Present Value (USD Million)
14.4.5.39.3. Value Creation Analysis
15. PROMOTIONAL ANALYSIS
15.1. Chapter Overview
15.2. Channels Used for Promotional Campaigns
15.3. Summary of Product Website Analysis
15.4. Summary of Patient Support Services and Informative Downloads
15.5. Kymriah®: Promotional Analysis
15.5.1. Drug Overview
15.5.2. Product Website Analysis
15.5.2.1. Message for Healthcare Professionals
15.5.2.2. Message for Patients
15.5.2.3. Informative Downloads
15.5.3. Patient Support Services
15.6. Yescarta®: Promotional Analysis
15.6.1. Drug Overview
15.6.2. Product Website Analysis
15.6.2.1. Message for Healthcare Professionals
15.6.2.2. Message for Patients
15.6.2.3. Informative Downloads
15.6.3. Patient Support Services
15.7. Tecartus®: Promotional Analysis
15.7.1. Drug Overview
15.7.2. Product Website Analysis
15.7.2.1. Message for Healthcare Professionals
15.7.2.2. Message for Patients
15.7.2.3. Informative Downloads
15.7.3. Patient Support Services
15.8. Breyanzi®: Promotional Analysis
15.8.1. Drug Overview
15.8.2. Product Website Analysis
15.8.2.1. Message for Healthcare Professionals
15.8.2.2. Message for Patients
15.8.2.3. Informative Downloads
15.8.3. Patient Support Services
15.9. Abecma®: Promotional Analysis
15.9.1. Drug Overview
15.9.2. Product Website Analysis
15.9.2.1. Message for Healthcare Professionals
15.9.2.2. Message for Patients
15.9.2.3. Informative Downloads
15.9.3. Patient Support Services
15.10. Carvykti®: Promotional Analysis
15.10.1. Drug Overview
15.10.2. Product Website Analysis
15.10.2.1. Message for Healthcare Professionals
15.10.2.2. Message for Patients
15.10.2.3. Informative Downloads
15.10.3. Patient Support Services
16. COMPANY PROFILES
16.1. Chapter Overview
16.2. Alaunos Therapeutics
16.3. Autolus
16.4. Bluebird Bio
16.5. Bristol Myers Squibb
16.6. Carsgen Therapeutics
16.7. Cellectis
16.8. Cellular Biomedicine Group
16.9. Gilead Sciences
16.10. Innovative Cellular Therapeutics
16.11. Kuur Therapeutics
16.12. Noile-Immune Biotech
16.13. Novartis
16.14. Shanghai GeneChem
16.15. Sinobioway Cell Therapy
16.16. Takara Bio
16.17. Wellington Zhaotai Therapies
17. CONCLUDING REMARKS
18. EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. Glycostem Therapeutics
18.2.1. Interview Transcript: Troels Jordansen, Chief Executive Officer
18.2. Gracell Biotechnologies
18.2.1. Interview Transcript: Wei (William) Cao, Chief Executive Officer
18.3. TxCell
18.3.1. Interview Transcript: Miguel Forte, Chief Operating Officer
18.4. Kite Pharma
18.4.1. Interview Transcript: Adrian Bot, Vice President, Scientific Affairs
18.5. Celyad
18.5.1. Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncologys
18.6. Waisman Biomanufacturing
18.6.1. Interview Transcript: Brian Dattilo, Manager of Business Development
18.7. Theravectys
18.7.1. Interview Transcript: Aino Kalervo, Former Competitive Intelligence Manager, Strategy & Business Development
18.8. Changhai Hospital
18.8.1. Interview Transcript: Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology
18.9. University of Colorado
18.9.1. Interview Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine
19. APPENDIX 1: TABULATED DATA
20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Clinical Trial Analysis
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Funding and Investments
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Pillars of Cancer Therapy
Figure 3.2 Differences between Active and Passive Immunotherapies
Figure 3.3 Differences between Specific and Non-Specific Immunotherapies
Figure 3.4 Strategies Employed for the Redirection of T-Cells
Figure 3.5 T-Cell Manufacturing: General Procedure
Figure 3.6 Development History of CAR-T cells
Figure 3.7 Structure of Chimeric Antigen Receptor
Figure 3.8 Chimeric Antigen Receptors: Structural Variations across Different Generations
Figure 3.9 CAR T-Cell Therapies: Development Process
Figure 3.10 Challenges Associated with CAR T-Cell Therapies
Figure 4.1 CAR T Cell Therapy: Distribution by Type of Developer
Figure 4.2 CAR T Cell Therapy: Distribution by Phase of Development
Figure 4.3 CAR T Cell Therapy: Distribution by Therapeutic Area
Figure 4.4 CAR T Cell Therapy: Distribution by Phase of Development and Therapeutic Area
Figure 4.5 CAR T Cell Therapy: Distribution by Key Target Indication
Figure 4.6 CAR T Cell Therapy: Distribution by Key Target Antigen
Figure 4.7 CAR T Cell Therapy: Distribution by Source of T-Cells
Figure 4.8 CAR T Cell Therapy: Distribution by Phase of Development and Source of T-Cells
Figure 4.9 CAR T Cell Therapy: Distribution by Route of Administration
Figure 4.10 CAR T Cell Therapy: Distribution by Dosing Frequency
Figure 4.11 CAR T Cell Therapy: Distribution by Target Patient Segment
Figure 4.12 CAR T Cell Therapy: Distribution by Type of Therapy
Figure 4.13 Most Active Industry Players: Analysis by Number of CAR-T Cell Therapies
Figure 4.14 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Figure 4.15 CAR-T Cell Therapy Developers Distribution by Year of Establishment
Figure 4.16 CAR-T Cell Therapy Developers: Distribution by Company Size
Figure 4.17 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.18 CAR T Cell Therapy: Distribution by Location of Headquarters (Country-wise)
Figure 5.1 CAR T Cell Therapy: Popular Targets in Hematological Malignancies
Figure 5.2 CAR T Cell Therapy: Popular Targets in Solid Tumors
Figure 5.3 CAR-Construction: Distribution by Generation of CAR
Figure 5.4 CAR-Construction: Distribution by Type of scFv Antibody
Figure 5.5 CAR-Construction: Distribution by Type of Virus Used
Figure 5.6 CAR-Construction: Distribution by Type of Gene Transfer Method Used
Figure 5.7 CAR-Construction: Distribution by Type of Co-Stimulatory Domain(s)
Figure 6.1 Clinical Trial Analysis: Scope and Methodology
Figure 6.2 Clinical Trial Analysis: Cumulative Distribution of trials by Trial Registration Year, Pre-2013-2022
Figure 6.3 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2013-2022
Figure 6.4 Clinical Trial Analysis: Distribution by Trial Status
Figure 6.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Figure 6.6 Clinical Trial Analysis: Distribution of Number of Trials by Trial Phase
Figure 6.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 6.8 Clinical Trial Analysis: Distribution by Target Patient
Figure 6.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 6.10 Clinical Trial Analysis: Distribution by Study Design
Figure 6.11 Most Active Players: Distribution by Number of Registered Trials
Figure 6.12 Most Active Players: Distribution by Number of Registered Trials
Figure 6.13 Clinical Trial Analysis: Key Focus Areas
Figure 6.14 Clinical Trial Analysis: Distribution of Trials by Geography
Figure 6.15 Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Figure 6.16 Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Figure 6.17 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Figure 7.1 CAR T-Cell Therapies KOL Analysis: Distribution by Type of Organization
Figure 7.2 CAR T-Cell Therapies KOL Analysis: Distribution by Affiliated Organization
Figure 7.3 CAR T-Cell Therapies KOL Analysis: Distribution by Qualification
Figure 7.4 CAR T-Cell Therapies: Geographical Distribution of KOLs
Figure 7.5 CAR T-Cell Therapies Scatter Plot: KOL Activenes s versus KOL Strength
Figure 7.6 Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 7.7 Most Prominent KOLs: Distribution by RA Score
Figure 7.8 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 7.9 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 8.1 Kymriah / Tisagenlecleucel: Estimated Sales Revenues
Figure 8.2 Yescarta / Axicabtagene Ciloleucel: Estimated Sales Revenues
Figure 8.3 Tecartus / Brexucabtagene Autoleucel: Estimated Sales Revenues
Figure 8.4 Breyanzi / Lisocabtagene Maraleucel: Estimated Sales Revenues
Figure 8.5 Abecma / Idecabtagene Vicleucel: Estimated Sales Revenues
Figure 8.6 Carvykti / Ciltacabtagene Autoleucel: Estimated Sales Revenues
Figure 8.7 Carteyva / Relmacabtagene Autoleucel: Estimated Sales Revenues
Figure 8.8 AUTO1: Estimated Sales Revenues
Figure 8.9 AUTO3: Estimated Sales Revenues
Figure 9.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2022
Figure 9.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Figure 9.5 Partnerships and Collaborations: Distribution by Type of partner
Figure 9.6 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner, Pre-2015-2022
Figure 9.7 Most Popular Products: Distribution by Number of Partnerships
Figure 9.8 Most Active Industry Players: Distribution by Number of Partnerships
Figure 9.9 Most Active Non-Industry Players: Distribution by Number of Partnerships
Figure 9.10 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Figure 9.11 Partnerships and Collaborations: Distribution of International and Local Deals
Figure 10.1 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Pre-2018 - 2022
Figure 10.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Pre-2018 - 2022 (USD Million)
Figure 10.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 10.4 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Figure 10.5 Funding and Investments: Distribution by Types of Investors
Figure 10.6 Funding and Investments: Distribution of Amount Invested by Type of Investor (USD Million)
Figure 10.7 Most Active Players: Distribution by Number of Instances
Figure 10.8 Most Active Players: Distribution by Amount Invested (USD Million
Figure 10.9 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Figure 11.1 Patent Analysis: Distribution by Type of Patent
Figure 11.2 Patent Analysis: Cumulative Distribution by Patent Publication Year
Figure 11.3 Patent Analysis: Cumulative Distribution Patent Application Year
Figure 11.4 Patent Analysis: Cumulative Distribution by Annual Granted Patents
Figure 11.5 Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Figure 11.6 Patent Analysis: Distribution of Year-wise Granted Patents and Patent Applications
Figure 11.7 Patent Analysis: Distribution by Geography
Figure 11.8 Patent Analysis: Distribution by Type of Player
Figure 11.9 Patent Analysis: Distribution by CPC Symbols
Figure 11.10 Patent Analysis: Key Focus Area
Figure 11.11 Leading Industry Players: Distribution by Number of Patents
Figure 11.12 Leading Non-Industry Players: Distribution by Number of Patents
Figure 11.13 Leading Patent Assignees: Distribution by Number of Patents
Figure 11.14 Patent Analysis (Top 9 CPC Symbols): Benchmarking by Leading Players
Figure 11.15 Patent Analysis: Distribution by Patent Age
Figure 11.14 CAR T Cell Therapy: Patent Valuation Analysis
Figure 12.1 Steps for Manufacturing Cell Therapies
Figure 12.2 Centralized Manufacturing: Process Model
Figure 12.3 Decentralized Manufacturing: Process Model
Figure 12.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 12.5 Cell Therapy: Challenges and Drivers
Figure 12.6 Cell Therapies: Potency as Critical Quality Attribute
Figure 12.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 12.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 13.1 Approved T-Cell Therapies: Pricing Model based on Patient Segment
Figure 14.1 Global CAR T Cell Therapy Market, 2022-2035 (USD Billion)
Figure 14.2 CAR T Cell Therapy Market: Distribution by Target Indication(s), 2025 and 2035 (USD Billion)
Figure 14.3 CAR T Cell Therapy Market: Distribution by Target Antigen(s), 2025 and 2035 (USD Billion)
Figure 14.4 CAR T Cell Therapy Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Figure 14.5 CAR T Cell Therapy Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Figure 14.6 Kymriah® / Tisagenlecleucel / CTL019 (Novartis) Sales Forecast, till 2035 (USD Million)
Figure 14.7 Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences) Sales Forecast, till 2035 (USD Million)
Figure 14.8 Tecartus / Brexucabtagene Autoleucel (Gilead Sciences) Sales Forecast, till 2035 (USD Million)
Figure 14.9 Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb) Sales Forecast, till 2035 (USD Million)
Figure 14.10 Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen) Sales Forecast, till 2035 (USD Million)
Figure 14.11 Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb) Sales Forecast, till 2035 (USD Million)
Figure 14.12 Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.13 BCMA CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Figure 14.14 CD19 CAR-T (Wuhan Si'an Medical Technology) Sales Forecast, till 2035 (USD Million)
Figure 14.15 Descartes-11 (Cartesian Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.16 Descartes-08 (Cartesian Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.17 Zamtocabtagene Autoleucel MB-CART19.1 (Miltenyi Biomedicine) Sales Forecast, till 2035 (USD Million)
Figure 14.18 CNCT19 / HY001 (Juventas Cell Therapy) Sales Forecast, till 2035 (USD Million)
Figure 14.19 CD30.CAR-T / TT11 (Tessa Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.20 TAK-007 (Takeda) Sales Forecast, till 2035 (USD Million)
Figure 14.21 AUTO1 (Autolus) Sales Forecast, till 2035 (USD Million)
Figure 14.22 AUTO3 (Autolus) Sales Forecast, till 2035 (USD Million)
Figure 14.23 CD19 CAR-T (Bioray Laboratories) Sales Forecast, till 2035 (USD Million)
Figure 14.24 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology, till 2035 (USD Million)
Figure 14.25 IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2035 (USD Million)
Figure 14.26 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2035 (USD Million)
Figure 14.27 BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2035 (USD Million)
Figure 14.28 CARCIK-CD19 (CoImmune) Sales Forecast, till 2035 (USD Million)
Figure 14.29 PBCAR269A (Precision BioSciences / Servier) Sales Forecast, till 2035 (USD Million)
Figure 14.30 CD123 CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 14.31 BCMA CAR-T (Chongqing Precision Biotech) Sales Forecast, till 2035 (USD Million)
Figure 14.32 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Figure 14.33 GC012F / DUAL CAR-BCMA-19 (Gracell Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 14.34 IC9-CAR19 T Cells (Bellicum Pharmaceuticals) Sales Forecast, till 2035 (USD Million)
Figure 14.35 ALLO-501A / ALLO-501 (Allogene Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.36 CD19/CD20-CAR-T (Yake Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 14.37 CD7 CAR-T (PersonGen BioTherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.38 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.39 CT053 (CARsgen Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.40 Anti-ALPP CAR-T Cells (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Figure 14.41 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 14.42 ALLO-605 (Allogene Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.43 WU CART 007 (WUGEN) Sales Forecast, till 2035 (USD Million)
Figure 14.44 CT103A (Nanjing IASO Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 15.1 Channels Used for Promotional Campaigns
Figure 15.2 Promotional / Marketing Strategy: Product Website Analysis
Figure 15.3 Product Website Analysis: Kymriah, Messages for Healthcare Professionals
Figure 15.4 Product Website Analysis: Kymriah, Messages for Patients
Figure 15.5 Product Website Analysis: Kymriah, Patient Support Program
Figure 15.6 Product Website Analysis: Yescarta, Messages for Healthcare Professionals
Figure 15.7 Product Website Analysis: Yescarta, Messages for Patients
Figure 15.8 Product Website Analysis: Yescarta, Kite Konnect
Figure 15.9 Product Website Analysis: Yescarta, Platform for Referral Patient Treatment and Connecting with Treatment Center
Figure 15.10 Product Website Analysis: Tecartus, Messages for Healthcare Professionals
Figure 15.11 Product Website Analysis: Tecartus, Messages for Patients
Figure 15.12 Product Website Analysis: Tecartus, Kite Konnect
Figure 15.13 Product Website Analysis: Breyanzi, Messages for Healthcare Professional
Figure 15.14 Product Website Analysis: Breyanzi, Messages for Patients
Figure 15.15 Product Website Analysis: Breyanzi, Cell Therapy 360
Figure 15.16 Product Website Analysis: Abecma, Messages for Healthcare Professional
Figure 15.17 Product Website Analysis: Abecma, Messages for Patients
Figure 15.18 Product Website Analysis: Abecma, Cell Therapy 360
Figure 15.19 Product Website Analysis: Carvykti, Messages for Healthcare Professional
Figure 15.20 Product Website Analysis: Carvykti, Messages for Patients
Figure 15.21 Product Website Analysis: Carvykti, MyCARVYKTI
Figure 17.1 Concluding Remarks: Market Landscape
Figure 17.2 Concluding Remarks: Clinical Trial Analysis
Figure 17.3 Concluding Remarks: Key Opinion Leaders
Figure 17.4 Concluding Remarks: Partnerships & Collaborations
Figure 17.5 Concluding Remarks: Funding and Investment Analysis
Figure 17.6 Concluding Remarks: Patent Analysis
Figure 17.7 Concluding Remarks: Market Forecast
Table 2.1 Biosensors in Drug Discovery: List of Companies
Table 3.1 Types of Immunotherapies and Affiliated Mechanisms of Action
Table 3.2 FDA Approved Antibody based Cancer Therapeutics
Table 3.5 Key Characteristics of CAR-T Cells
Table 3.6 Comparison of First and Second-Generation CAR-Ts
Table 3.7 CD19 CAR-T Cells: Preclinical Results
Table 3.8 Other Targets under Clinical / Preclinical Studies for CAR-T Cell Therapies
Table 4.1 CAR T Cell Therapy: Clinical Pipeline
Table 4.2 CAR T Cell Therapy: Information on Route of Administration, Source of T-Cells, Target Patient Segment, Type of Therapy and Dosing Frequency
Table 4.3 CAR T Cell Therapy: Preclinical Pipeline
Table 4.4 List of CAR-T Cells Developers
Table 5.1 CAR-T Therapies: Information on Constructs of Clinical Candidates
Table 8.1 CAR T Cell Therapy: List of Therapies Profiled
Table 8.2 Therapy Profile: Kymriah® / Tisagenlecleucel (Novartis)
Table 8.3 Kymriah / Tisagenlecleucel: Clinical Trial Information
Table 8.4 Kymriah / Tisagenlecleucel: Clinical Trial Endpoints
Table 8.5 Kymriah / Tisagenlecleucel: Clinical Trial Results
Table 8.6 Therapy Profile: Yescarta / Axiscabtagene Ciloleucel (Gilead Sciences)
Table 8.7 Yescarta / Axiscabtagene Ciloleucel: Clinical Trial Information
Table 8.8 Yescarta / Axiscabtagene Ciloleucel: Clinical Trial Endpoints
Table 8.9 Yescarta / Axiscabtagene Ciloleucel: Clinical Trial Results
Table 8.10 Therapy Profile: Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
Table 8.11 Tecartus / Brexucabtagene Autoleucel: Clinical Trial Information
Table 8.12 Tecartus / Brexucabtagene Autoleucel: Clinical Trial Endpoints
Table 8.13 Tecartus / Brexucabtagene Autoleucel: Clinical Trial Results
Table 8.14 Therapy Profile: Breyanzi / Lisocabtagene Maraleucel (Bristol Myers Squibb)
Table 8.15 Breyanzi / Lisocabtagene Maraleucel: Clinical Trial Information
Table 8.16 Breyanzi / Lisocabtagene Maraleucel: Clinical Trial Endpoints
Table 8.17 Breyanzi / Lisocabtagene Maraleucel: Clinical Trial Results
Table 8.18 Therapy Profile: Abecma / Idecabtagene Vicleucel (Bristol Myers Squibb)
Table 8.19 Abecma / Idecabtagene Vicleucel: Clinical Trial Information
Table 8.20 Abecma / Idecabtagene Vicleucel: Clinical Trial Endpoints
Table 8.21 Abecma / Idecabtagene Vicleucel: Clinical Trial Results
Table 8.22 Therapy Profile: Carvykti / Ciltacabtagene Autoleucel (Janssen)
Table 8.23 Carvykti / Ciltacabtagene Autoleucel: Clinical Trial Information
Table 8.24 Carvykti / Ciltacabtagene Autoleucel: Clinical Trial Endpoints
Table 8.25 Carvykti / Ciltacabtagene Autoleucel: Clinical Trial Results
Table 8.26 Therapy Profile: Carteyva / Relmacabtagene Autoleucel (JW Therapeutics)
Table 8.27 Carteyva / Relmacabtagene Autoleucel: Clinical Trial Information
Table 8.28 Carteyva / Relmacabtagene Autoleucel: Clinical Trial Endpoints
Table 8.29 Carteyva / Relmacabtagene Autoleucel: Clinical Trial Results
Table 8.30 Therapy Profile: TBI-1501 (Takara Bio)
Table 8.31 TBI-1501: Clinical Trial Information
Table 8.32 TBI-1501: Clinical Trial Endpoints
Table 8.33 Therapy Profile: AUTO1 (Autolus)
Table 8.34 AUTO1: Clinical Trial Information
Table 8.35 AUTO1: Clinical Trial Endpoints
Table 8.36 AUTO1: Clinical Trial Results
Table 8.37 Therapy Profile: AUTO3 (Autolus)
Table 8.38 AUTO3: Clinical Trial Information
Table 8.39 AUTO3: Clinical Trial Endpoints
Table 8.40 AUTO3: Clinical Trial Results
Table 9.1 CAR T Cell Therapy: List of Partnerships and Collaborations, 2005-2022
Table 10.1 CAR T Cell Therapy: Funding and Investments, 2000-2022
Table 10.2 CAR T Cell Therapy: Summary of Investments
Table 11.1 Patent Analysis: Prominent CPC Symbols
Table 11.2 Patent Analysis: Most Popular CPC Symbols
Table 11.3 Patent Analysis: List of Top CPC Symbols
Table 11.4 Patent Analysis: Summary of Benchmarking Analysis
Table 11.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 12.1 Assessment Strategies for Different Manufacturing Processes
Table 12.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 12.3 Cell Therapy Manufacturing: Companies with In-House Capabilities and Contract Manufacturers
Table 13.1 Price of Marketed Gene / Cell Therapies
Table 13.2 Price of Marketed Targeted Drugs
Table 13.3 CAR T Cell Therapy: Expert Opinions on Pricing
Table 13.4 CAR T Cell Therapy: Reimbursement Landscape
Table 14.1 CAR T Cell Therapy: List of Forecasted Molecules
Table 14.2 Kymriah / Tisagenlecleucel (Novartis): Net Present Value (USD Million)
Table 14.3 Kymriah / Tisagenlecleucel (Novartis): Value Creation Analysis (USD Million)
Table 14.4 Yescarta / Axiscabtagene Ciloleucel (Gilead Sciences): Net Present Value (USD Million)
Table 14.5 Yescarta / Axiscabtagene Ciloleucel (Gilead Sciences): Value Creation Analysis (USD Million)
Table 14.6 Tecartus / Brexucabtagene Autoleucel: (Gilead Sciences): Net Present Value (USD Million)
Table 14.7 Tecartus / Brexucabtagene Autoleucel: (Gilead Sciences): Value Creation Analysis (USD Million)
Table 14.8 Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb): Net Present Value (USD Million)
Table 14.9 Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb): Value Creation Analysis (USD Million)
Table 14.10 Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech /Janssen): Net Present Value (USD Million)
Table 14.11 Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech /Janssen): Value Creation Analysis (USD Million)
Table 14.12 Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb): Net Present Value (USD Million)
Table 14.13 Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb): Value Creation Analysis (USD Million)
Table 14.14 Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics): Net Present Value (USD Million)
Table 14.15 Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics): Value Creation Analysis (USD Million)
Table 14.16 BCMA CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 14.17 BCMA CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 14.18 CD19 CAR-T (Wuhan Si'an Medical Technology): Net Present Value (USD Million)
Table 14.19 CD19 CAR-T (Wuhan Si'an Medical Technology): Value Creation Analysis (USD Million)
Table 14.20 Descartes-11 (Cartesian Therapeutics): Net Present Value (USD Million)
Table 14.21 Descartes-11 (Cartesian Therapeutics): Value Creation Analysis (USD Million)
Table 14.22 Descartes-08 (Cartesian Therapeutics): Net Present Value (USD Million)
Table 14.23 Descartes-08 (Cartesian Therapeutics): Value Creation Analysis (USD Million)
Table 14.24 Zamtocabtagene Autoleucel MB-CART19.1 (Miltenyi Biomedicine): Net Present Value (USD Million)
Table 14.25 Zamtocabtagene Autoleucel MB-CART19.1 (Miltenyi Biomedicine): Value Creation Analysis (USD Million)
Table 14.26 CNCT19 / HY001 (Juventas Cell Therapy): Net Present Value (USD Million)
Table 14.27 CNCT19 / HY001 (Juventas Cell Therapy): Value Creation Analysis (USD Million)
Table 14.28 CD30.CAR-T / TT11 (Tessa Therapeutics): Net Present Value (USD Million)
Table 14.29 CD30.CAR-T / TT11 (Tessa Therapeutics): Value Creation Analysis (USD Million)
Table 14.30 TAK-007 (Takeda): Net Present Value (USD Million)
Table 14.32 TAK-007 (Takeda): Value Creation Analysis (USD Million)
Table 14.33 AUTO1 (Autolus): Net Present Value (USD Million)
Table 14.34 AUTO1 (Autolus): Value Creation Analysis (USD Million)
Table 14.35 AUTO3 (Autolus): Net Present Value (USD Million)
Table 14.36 AUTO3 (Autolus): Value Creation Analysis (USD Million)
Table 14.37 CD19 CAR-T (Bioray Laboratories): Net Present Value (USD Million)
Table 14.38 CD19 CAR-T (Bioray Laboratories): Value Creation Analysis (USD Million)
Table 18.39 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 20.40 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 14.41 IM19 CAR-T T (Beijing Immunochina Medical Science & Technology): Net Present Value (USD Million)
Table 14.42 IM19 CAR-T T (Beijing Immunochina Medical Science & Technology): Net Present Value (USD Million)
Table 14.43 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Net Present Value (USD Million)
Table 14.44 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Value Creation Analysis (USD Million)
Table 14.45 BinD19 (Shenzhen BinDeBio): Net Present Value (USD Million)
Table 14.46 BinD19 (Shenzhen BinDeBio): Value Creation Analysis (USD Million)
Table 14.47 CARCIK-CD19 (CoImmune): Net Present Value (USD Million)
Table 14.48 CARCIK-CD19 (Formula Pharmaceuticals): Value Creation Analysis (USD Million)
Table 14.49 PBCAR269A (Precision BioSciences / Servier): Net Present Value (USD Million)
Table 14.50 PBCAR269A (Precision BioSciences and Servier): Value Creation Analysis (USD Million)
Table 14.51 CD123 CAR-T cells (Chongqing Precision Biotechnology): Net Present Value (USD Million)
Table 14.52 CD123 CAR-T cells (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
Table 14.53 BCMA CAR-T (Chongqing Precision Biotech): Net Present Value (USD Million)
Table 14.54 BCMA CAR-T (Chongqing Precision Biotech): Value Creation Analysis (USD Million)
Table 14.55 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 14.56 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 14.57 GC012F / DUAL CAR-BCMA-19 (Gracell Biotechnology): Net Present Value (USD Million)
Table 14.58 GC012F / DUAL CAR-BCMA-19 (Gracell Biotechnology): Value Creation Analysis (USD Million)
Table 14.59 IC9-CAR19 T Cells (Bellicum Pharmaceuticals): Net Present Value (USD Million)
Table 14.60 IC9-CAR19 T Cells (Bellicum Pharmaceuticals): Value Creation Analysis (USD Million)
Table 14.61 ALLO-501A / ALLO-501 (Allogene Therapeutics): Net Present Value (USD Million)
Table 14.62 ALLO-501A / ALLO-501 (Allogene Therapeutics): Value Creation Analysis (USD Million)
Table 14.63 CD19/CD20-CAR-T (Yake Biotechnology): Net Present Value (USD Million)
Table 14.64 CD19/CD20-CAR-T (Yake Biotechnology): Value Creation Analysis (USD Million)
Table 14.65 CD7 CAR-T (PersonGen BioTherapeutics): Net Present Value (USD Million)
Table 14.66 CD7 CAR-T (PersonGen BioTherapeutics): Value Creation Analysis (USD Million)
Table 14.67 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics): Net Present Value (USD Million)
Table 14.68 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics): Value Creation Analysis (USD Million)
Table 14.69 CT053 (CARsgen Therapeutics): Net Present Value (USD Million)
Table 14.70 CT053 (CARsgen Therapeutics): Value Creation Analysis (USD Million)
Table 14.71 Anti-ALPP CAR-T Cells (TCRCure Biopharma): Net Present Value (USD Million)
Table 14.72 Anti-ALPP CAR-T Cells (TCRCure Biopharma): Value Creation Analysis (USD Million)
Table 14.73 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology): Net Present Value (USD Million)
Table 14.74 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
Table 14.75 ALLO-605 (Allogene Therapeutics): Net Present Value (USD Million)
Table 14.76 ALLO-605 (Allogene Therapeutics): Value Creation Analysis (USD Million)
Table 14.77 WU CART 007 (WUGEN): Net Present Value (USD Million)
Table 14.78 WU CART 007 (WUGEN): Value Creation Analysis (USD Million)
Table 14.79 CT103A (Nanjing IASO Biotherapeutics): Net Present Value (USD Million)
Table 14.80 CT103A (Nanjing IASO Biotherapeutics): Value Creation Analysis (USD Million)
Table 15.1 Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
Table 15.2 Kymriah / Tisagenlecleucel: Drug Overview
Table 15.3 Yescarta / Axiscabtagene Ciloleucel: Drug Overview
Table 15.4 Tecartus / Brexucabtagene Autoleucel: Drug Overview
Table 15.5 Breyanzi / Lisocabtagene Maraleucel: Drug Overview
Table 15.6 Abecma / Idecabtagene Vicleucel: Drug Overview
Table 15.7 Carvykti / Ciltacabtagene Autoleucel: Drug Overview
Table 16.1 Leading CAR-T Cell Therapy Developers
Table 16.2 Autolus: Company Profile
Table 16.3 bluebird bio: Company Profile
Table 16.4 Bristol Myers Squibb: Company Profile
Table 16.5 CARsgen Therapeutics: Company Profile
Table 16.6 Cellectis: Company Profile
Table 16.7 Cellular Biomedicine Group: Company Profile
Table 16.8 Gilead Sciences: Company Profile
Table 16.9 Innovative Cellular Therapeutics: Company Profile
Table 16.10 Kuur Therapeutics: Company Profile
Table 16.11 Noile-Immune Biotech: Company Profile
Table 16.12 Novartis: Company Profile
Table 16.13 Shanghai Genechem: Company Profile
Table 16.14 Sinobioway Cell Therapy: Company Profile
Table 16.15 Takara Bio: Company Profile
Table 16.16 Wellington Zhaotai Therapies: Company Profile
Table 19.1 CAR T Cell Therapy: Distribution by Type of Developer
Table 19.2 CAR T Cell Therapy: Distribution by Phase of Development
Table 19.3 CAR T Cell Therapy: Distribution by Target Therapeutic Area
Table 19.4 CAR T Cell Therapy: Distribution by Phase of Development and Therapeutic Area
Table 19.5 CAR T Cell Therapy: Distribution by Key Target Indications
Table 19.7 CAR T Cell Therapy: Distribution by Source of T-Cells
Table 19.8 CAR T Cell Therapy: Distribution by Phase of Development and Source of T-Cell
Table 19.9 CAR T Cell Therapy: Distribution by Route of Administration
Table 19.10 CAR T Cell Therapy: Distribution by Dosing Frequency
Table 19.11 CAR T Cell Therapy: Distribution by Target Patient Segment
Table 19.12 CAR T Cell Therapy: Distribution by Type of Therapy
Table 19.13 Most Active Industry Players: Distribution by Number of CAR-T Cell Therapies
Table 19.14 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Table 19.15 CAR-T Cell Therapy Developers: Distribution by Year of Establishment
Table 19.16 CAR-T Cell Therapy Developers: Distribution by Company Size
Table 19.17 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Table 19.18 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Table 19.19 CAR T Cell Therapy Clinical Trial Analysis: Cumulative Distribution of Trials by Trial Registration Year
Table 19.20 CAR T Cell Therapy Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Table 19.21 CAR T Cell Therapy Clinical Trial Analysis: Distribution by Trial Status
Table 19.22 CAR T Cell Therapy Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 19.23 CAR T Cell Therapy Clinical Trial Analysis: Distribution of Number of Trials by Trial Phase
Table 19.24 CAR T Cell Therapy Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 19.25 CAR T Cell Therapy Clinical Trial Analysis: Distribution by Target Patient Segment
Table 19.26 CAR T Cell Therapy Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 19.27 CAR T Cell Therapy Clinical Trial Analysis: Distribution by Study Design
Table 19.28 Most Active Industry Players: Distribution by Number of Registered Trials
Table 19.29 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 19.30 CAR T Cell Therapy Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 19.31 CAR T Cell Therapy Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Table 19.32 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Table 19.33 CAR T Cell Therapy Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Table 19.34 CAR T Cell Therapy KOL Analysis: Distribution by Type of Organization
Table 19.35 CAR T Cell Therapy KOL Analysis: Distribution by Affiliated Organization
Table 19.36 CAR T Cell Therapy KOL Analysis: Distribution by Qualification
Table 19.37 CAR T Cell Therapy: Geographical Distribution of KOLs
Table 19.38 CAR T Cell Therapy Most Prominent KOLs: Distribution by RA Score
Table 19.39 CAR T Cell Therapy Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 19.40 Kymriah / Tisagenlecleucel: Estimated Sales Revenues
Table 19.41 Yescarta / Axicabtagene Ciloleucel: Estimated Sales Revenues
Table 19.42 Tecartus / Brexucabtagene Autoleucel: Estimated Sales Revenues
Table 19.43 Breyanzi / Lisocabtagene Maraleucel: Estimated Sales Revenues
Table 19.44 Abecma / Idecabtagene Vicleucel: Estimated Sales Revenues
Table 19.45 Carvykti / Ciltacabtagene Autoleucel: Estimated Sales Revenues
Table 19.46 Carteyva / Relmacabtagene Autoleucel: Estimated Sales Revenues
Table 19.47 AUTO1: Estimated Sales Revenues
Table 19.48 AUTO3: Estimated Sales Revenues
Table 19.49 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Table 19.50 Partnerships and Collaborations: Distribution by Type of Partnership
Table 19.51 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2022
Table 19.52 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 19.53 Partnerships and Collaborations: Distribution by Type of Partner
Table 19.54 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner
Table 19.55 Most Popular Products: Distribution by Number of Partnerships
Table 19.56 Most Active Industry Players: Distribution by Number of Partnerships
Table 19.57 Most Active Non-Industry Players: Distribution by Number of Partnerships
Table 19.58 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Table 19.59 Partnerships and Collaborations: Distribution of International and Local Agreements
Table 19.60 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Pre-2018 – 2022
Table 19.61 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Pre-2018 -2022 (USD Million)
Table 19.62 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 19.63 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 19.64 Funding and Investments: Distribution by Type of Investors
Table 19.65 Funding and Investments: Distribution of Amount Invested by Type of Investor (USD Million)
Table 19.66 Most Active Players: Distribution by Number of Instances
Table 19.67 Most Active Players: Distribution by Amount Invested (USD Million)
Table 19.68 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Table 19.69 Most Active Investors: Distribution by Number of Funding Instances
Table 19.70 Patent Analysis: Distribution by Type of Patent
Table 19.71 CAR T Cell Therapy Patent Analysis: Cumulative Distribution by Patent Publication Year
Table 19.72 CAR T Cell Therapy Patent Analysis: Cumulative Distribution by Patent Application Year
Table 19.73 CAR T Cell Therapy Patent Analysis: Cumulative Distribution by Annual Granted Patents
Table 19.74 CAR T Cell Therapy Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Table 19.75 CAR T Cell Therapy Patent Analysis: Distribution of Year-wise Granted Patents and Patent Applications
Table 19.76 CAR T Cell Therapy Patent Analysis: Distribution by Geography
Table 19.77 CAR T Cell Therapy Patent Analysis: Distribution by Type of Player
Table 19.78 CAR T Cell Therapy Patent Analysis: Distribution by CPC Symbols
Table 19.79 Leading Industry Players: Distribution by Number of Patents
Table 19.80 Leading Non-Industry Players: Distribution by Number of Patents
Table 19.81 Leading Patent Assignees: Distribution by Number of Patents
Table 19.82 Patent Analysis: Distribution by Patent Age
Table 19.83 CAR-T Therapies: Patent Valuation Analysis
The following companies / institutes / government bodies and organizations have been mentioned in this report:
Source 1: https://www.cancer.org/research/cancer-facts-statistics/global.html
Source 2: https://www.nature.com/articles/s41587-022-01212-6